Exclusive Webinar: Unpacking the Future of U.S. Drug Pricing Policy

Gain immediate access to actionable insights from CMS and ADVI Health policy leaders.

From the Medicare Drug Price Negotiation Program to MFN pricing approaches (including the GENEROUS, GLOBE, and GUARD models) and evolving 340B requirements, biopharmaceutical stakeholders are navigating a highly fluid regulatory environment.

Understanding how these policy shifts intersect, and how they directly impact your pricing strategy, product launches, and commercialization plans, is critical for staying competitive.

Fill out the form to unlock the full webinar recording and learn:

• Where Key Policies Stand: Breakdown of recent developments across Medicare negotiations, MFN models, and 340B reform.
• Commercial & Access Implications: How intersecting state, federal, and global policies influence market access and long-term spending strategies.
• What to Expect Next: Key implementation milestones, unanswered policy questions, and potential risks to pipeline innovation and investment.

Featured Panelists

• Lindsay Bealor Greenleaf — SVP, Market Access & Policy Strategy, ADVI Health
• Alicia Silver — VP, Emerging Therapies, ADVI Health
• Brenna Raines (Moderator) — VP, Market Access & Policy Strategy, ADVI Health

Submit your details in the form to start watching immediately.

---